And patients with malignant melanoma, non-small cell lung cancer (NSCLC), or renal cell carcinoma are beneficial from anti-PD-1 and anti-PD-L1 therapy [5, 10, 14, 15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.